Overview

A Single-dose Trial to Investigate the Safety and Tolerability of XEN-D0501 in Patients With Diabetes Mellitus Type 2

Status:
Completed
Trial end date:
2018-11-13
Target enrollment:
Participant gender:
Summary
This is a single-dose dose escalation trial in a randomised, single-blind, placebo-controlled group-comparison design to investigate the safety and tolerability of XEN-D0501 in subjects with diabetes mellitus type 2 where life style changes and treatment with metformin has failed to effectively reduce blood glucose concentrations.
Phase:
Phase 2
Details
Lead Sponsor:
Pila Pharma